saxagliptin (onglyza) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Saxagliptin is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release] DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.2540

United States

$10.2347 - $14.6136
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1s,3s,5s)-2-((2s)-2-amino-2-(3-hydroxyadamantan-1-yl) acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile hydrate | (1s,3s,5s)-2-((2s)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | bms477118 | bms 477118 | bms-477118 | bms-477118-11 | metformin hydrochloride /saxagliptin hydrochloride | onglyza | saxagliptin | saxagliptin anhydrous | saxagliptin / dapagliflozin propanediol monohydrate | saxagliptin hcl | saxagliptin hydrate | saxagliptin hydrochloride

Organizations (89)

Research & Development (81)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Albuminuria (Phase 4)

Blood Glucose (Phase 3)

Cardiovascular Diseases (Phase 4)

Catecholamines (Early Phase 1)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 ()

Diabetic Foot (Phase 4)

Drugs, Generic (Phase 1)

Exercise (Early Phase 1)

Glucose Intolerance (Phase 4)

Glycemic Control (Phase 4)

Heart Failure (Phase 4)

Hyperglycemia (Phase 4)

Hypertriglyceridemia (Phase 4)

Hypoglycemia (Phase 3)

Insulin Resistance (Phase 2)

Myocardial Infarction (Phase 3)

Obesity (Phase 4)

Polycystic Ovary Syndrome (Phase 3)

Prediabetic State (Phase 4)

Sympathetic Nervous System (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 117
  • # of Trial Organizations: 81

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue